Meta-analysis reveals improved overall survival and progression-free survival with daratumumab in high-risk multiple myeloma, highlighting its efficacy in enhancing treatment.
Key Points
Daratumumab combined with standard therapy significantly improves overall survival and progression-free survival in patients with high-risk multiple myeloma.
The meta-analysis included 11 studies with 4993 patients, demonstrating higher objective response rates in the experimental group (P < 0.05).
Quality assessment indicated all studies had a low to moderate risk of bias, ensuring reliable evidence for clinical application.
Results suggest that while daratumumab reduces anemia incidence, it increases the frequency of thrombocytopenia and neutropenia, with overall manageable adverse effects.